Business Strategy
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
UroGen Approaches A Big Expansion In Bladder Cancer
The oncology company is preparing for the launch of UGN-102 for bladder cancer. CEO Liz Barrett talked to Scrip about the company’s next growth phase.
Fennec Finds Ex-US Commercial Partner For Pedmark In UK’s Norgine
Norgine will market Pedmark, indicated to reduce risk of chemotherapy-related hearing loss in pediatric cancer, in the EU and UK. It will seek additional approvals in Australia and New Zealand.
Moonlake Aims To Defy The Single-Product Risk
The group is pushing sonelokimab into pivotal trials in two indications and starting from scratch in three more. What comes after that?
Could ASEAN Become Next Priority For Korean Pharma Firms?
Southeast Asia has so far not been a priority market for South Korean pharma firms, largely because of challenges such as access and affordability for patients. But a Deloitte executive suggested at a recent seminar that technology-based medicines, for example using next-generation formulation technologies, could be an initial focus for Korean firms looking to enter the rapidly growing ASEAN grouping.
Madrigal Has A Slow, Steady Launch Planned For Rezdiffra
Madrigal faces the challenge of opening the metabolic-associated steatohepatitis (MASH, also known as NASH) market, but the firm has been laying groundwork for over a year.
Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
Moeller Looks To Prove BenevolentAI’s Doubters Wrong
The former Bayer research head needs to turn the AI-based company around, but investors are skeptical about its attempts to serve big pharma and develop its own pipeline simultaneously.
Andera Reflects On Revitalized Biotech Scene
After AstraZeneca’s acquisition of Amolyt made the Paris-based investment group a tidy profit, Andera spoke to Scrip about the rejuvenated investment market in Europe.
Cybin High On Psychedelic-Based CYB003 For MDD
The company will initiate a Phase III program in mid-2024, testing the deuterated psilocybin analog as an adjunctive treatment for depression on top of SSRIs.
AstraZeneca Spends $800m On Amolyt And Awaits A Readout
The Phase III trial of hypoparathyroidism asset eneboparatide will have to hit if AstraZeneca is going to carve out market share from Ascendis.
Tubulis Touts Transatlantic Plans As Cash Rolls In
The German biotech is benefitting from the heat in the antibody-drug conjugate space and has concluded an upsized series B2 financing for €128m.
Chinese ADC Developers Unveil More Target Combos In Bispecific Drive
Chinese developers are racing to roll out bispecific ADCs with different target combinations, while a Biokin/SysImmune executive estimates more than $20bn in annual sales for the company's BMS-partnered EGFR x HER3 candidate, as R&D in the field continues to surge ahead in China.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.